- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07943312
GA001 Injection in Retinitis Pigmentosa
A Clinical Study to Evaluate the Safety and Efficacy of GA001 Injection in Patients With Retinitis Pigmentosa
This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Retinitis pigmentosa (RP) is an inherited retinal disease that causes gradual vision loss and can lead to blindness, with no approved curative treatment currently available.
This Phase II study is designed to evaluate the safety, tolerability, and efficacy of a single unilateral intravitreal injection of GA001 Injection at the target dose compared with sham injection in patients with retinitis pigmentosa. The study employs a sham-controlled design and will assess safety and efficacy outcomes as well as multiple functional and structural measures of visual performance over long-term follow-up.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Xiaodong Sun Principal Investigator, PhD
- Numéro de téléphone: 86 17853138155
- E-mail: xdsun@sjtu.edu.cn
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200080
- Shanghai General Hospital
-
Contact:
- Xiaodong Sun
- Numéro de téléphone: 86-1566269037
- E-mail: guanranzhang@126.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female participants aged 18 to 70 years.
- Clinical diagnosis of advanced retinitis pigmentosa (RP).
- Best corrected visual acuity at or below the protocol-defined threshold in the study eye.
- Ability to understand and sign informed consent (and assent, when applicable).
- Laboratory test results are within the protocol-defined threshold range.
Exclusion Criteria:
- Presence of other ocular conditions that could interfere with study assessments.
- History of significant ocular surgery in the study eye within a protocol-defined period.
- Active ocular infection or inflammation.
- Clinically significant systemic disease that could increase study risk or interfere with assessments.
- Positive screening for clinically significant infectious diseases, as defined in the protocol.
- Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation.
- Pregnant or breastfeeding individuals.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: GA001
|
Single unilateral IVT injection of GA001 Injection in the study eye |
|
Comparateur factice: Sham Injection
|
Sham IVT procedure in the study eye |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To evaluate the efficacy of GA001 Injection in patients with retinitis pigmentosa
Délai: Baseline to Week 52
|
BCVA-Change from Baseline in LogMAR Best Corrected Visual Acuity (BCVA) BCVA assessed by ETDRS charts at each post-treatment visit compared with the sham group.baseline→W52,Unit: LogMAR MLMT-Change from Baseline in Multi-Luminance Mobility Test (MLMT) Performance MLMT 7 levels; baseline→W52 ambient Lux to finish course, vs. sham. Unit: Lux Light Sensitivity-Change from Baseline in Light Sensitivity (Minimum Identifiable Brightness) Min brightness (Lux), study eye; baseline→W52, vs. sham. Unit: Lux FST Threshold-Change from Baseline in Full-Field Stimulus Test (FST) Threshold Full-field stimulus test; baseline→W52, vs. sham. Unit: log cd·s/m² Central Visual Field-Change from Baseline in Central Visual Field Static perimetry; baseline→W52, vs. sham. Unit: dB (mean deviation) MRDQ-Change from Baseline in Michigan Retinal Degeneration Questionnaire (MRDQ) Total Score MRDQ total score; baseline→W52, vs. sham. Unit: total score (points) |
Baseline to Week 52
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events and serious adverse events
Délai: Baseline to Week 52
|
Incidence of severity of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following a single intravitreal injection of GA001 |
Baseline to Week 52
|
|
Evaluation of the Immunogenicity of GA001 Injection after a Single Intravitreal Administration in Patients with Retinitis Pigmentosa
Délai: Baseline to Week 52
|
Immunogenicity of GA001 Injection will be evaluated following a single intravitreal injection in patients with retinitis pigmentosa, by AAV neutralizing antibody titers in peripheral blood (cell-based neutralizing assay) and by analysis of GA001-specific T-cell immune responses. |
Baseline to Week 52
|
|
Maximum Concentration (Cmax) of GA001 Vector DNA
Délai: Baseline to Week 52
|
Cmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Area Under the Concentration-Time Curve (AUC) of GA001 Vector DNA
Délai: Baseline to Week 52
|
AUC of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Time to Maximum Concentration (Tmax) of GA001 Vector DNA
Délai: Baseline to Week 52
|
Tmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Biodistribution of GA001 Vector DNA
Délai: Baseline to Week 52
|
Biodistribution of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Shedding of GA001 Vector DNA
Délai: Baseline to Week 52
|
Shedding of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GA001-2025
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .